EBMT (Gratwohl) Transplant Risk Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- low0–1
- intermediate2–3
- high4–7
The EBMT (Gratwohl) Transplant Risk Score calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include age. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Pre-transplant risk score for allogeneic HSCT (0-7).
Clinical Indication
The EBMT (Gratwohl) Transplant Risk Score is indicated for bedside clinical practice to support Pre-transplant risk score for allogeneic HSCT (0-7).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Sum of 5 factors; total 0-7
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | string | Yes | Patient age |
| stage | string | Yes | Disease stage |
| interval | string | Yes | Time from diagnosis to transplant |
| donor | string | Yes | Donor type |
| sex_match | string | Yes | Donor-recipient sex combination |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | low | Low risk |
| 2–3 | intermediate | Intermediate risk |
| 4–7 | high | High risk |
Evidence-Based References (EBM)
- Gratwohl A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352(9134):1087-1092.